Linked Data API

Show Search Form

Search Results

227062
star this property registered interest false more like this
star this property date less than 2015-03-12more like thismore than 2015-03-12
star this property answering body
Wales Office more like this
star this property answering dept id 28 more like this
star this property answering dept short name Wales more like this
star this property answering dept sort name Wales more like this
star this property hansard heading Commission on Devolution in Wales more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will publish a table indicating, on the basis of the Secretary of State for Wales' St David's Day statement, which specific proposals of the Silk report have been rejected on the basis of failure to secure unanimity amongst the four consulted political parties; and which parties objected to each of the Silk proposals so rejected. more like this
star this property tabling member printed
Lord Wigley remove filter
unstar this property uin HL5701 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>Annex A of the Command Paper <em>Powers for a Purpose: Towards a Lasting Devolution Settlement in Wales</em> (Cm9020) sets out the Silk Commission’s recommendations and indicates where there was consensus and where there was none. It is for the political parties themselves to set out their view on particular Silk II recommendations.</p><p> </p><p> </p><p> </p> more like this
star this property answering member printed Baroness Randerson more like this
star this property question first answered
less than 2015-03-25T13:28:00.933Zmore like thismore than 2015-03-25T13:28:00.933Z
star this property answering member
4230
star this property label Biography information for Baroness Randerson more like this
unstar this property tabling member
547
unstar this property label Biography information for Lord Wigley more like this
228381
star this property registered interest false more like this
star this property date less than 2015-03-18more like thismore than 2015-03-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Mesothelioma more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what discussions they have had with the British Lung Foundation about progressing research into mesothelioma, and in particular taking research using adult stem cells to clinical trials. more like this
star this property tabling member printed
Lord Wigley remove filter
unstar this property uin HL5851 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the total health research expenditure of the Department of Health was devolved to and managed by National Health Service organisations. The NHS organisations reported on their use of these allocations in annual research and development reports. These reports identify total, aggregated expenditure on national priority areas, including cancer. They do not provide details of research into particular cancer sites. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. At the same time, an increasing amount of NHS research funding was awarded competitively through new NIHR programmes and schemes.</p><p> </p><p> </p><p> </p><p>Expenditure by the NIHR through research programmes, research centres and units, and research training awards on mesothelioma research is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>2006-07</p><p>£ million</p></td><td><p>2007-08</p><p>£ million</p></td><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£ million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£ million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Total spend by the NIHR on mesothelioma research is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>The NIHR invests in infrastructure for experimental medicine to translate scientific developments into benefits for patients. This infrastructure includes biomedical centres and units, clinical research facilities, and experimental cancer medicine centres. The NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London has contributed to the funding of recent research on the use of TRAIL (tumour necrosis factor-related apoptosis-inducing ligand)-expressing mesenchymal stem cells to reduce tumour growth in malignant mesothelioma.</p><p> </p><p> </p><p> </p><p>The following table provides expenditure by the Medical Research Council on research related to mesothelioma over the past six years. Information on spend from 2004-05 to 2007-08 was not available within the timescale.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£ million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£ million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.7</p></td><td><p>2.4</p></td><td><p>2.2</p></td><td><p>1.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>In April 2014, I convened a high level meeting between the Association of British Insurers and the British Lung Foundation (BLF) to discuss how insurers can remain engaged in support for mesothelioma research. Two insurers – Aviva and Zurich – who participated in the earlier donation by insurers of £3 million to the BLF, have agreed to each donate £250,000 per annum to the BLF for mesothelioma research over the next two years – a combined total of £1 million.</p><p> </p>
star this property answering member printed Earl Howe more like this
star this property grouped question UIN HL5852 more like this
star this property question first answered
less than 2015-03-25T16:19:48.7Zmore like thismore than 2015-03-25T16:19:48.7Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
unstar this property tabling member
547
unstar this property label Biography information for Lord Wigley more like this
228382
star this property registered interest false more like this
star this property date less than 2015-03-18more like thismore than 2015-03-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Mesothelioma more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what public sector funding has been provided in each of the past 10 years to support mesothelioma research. more like this
star this property tabling member printed
Lord Wigley remove filter
unstar this property uin HL5852 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the total health research expenditure of the Department of Health was devolved to and managed by National Health Service organisations. The NHS organisations reported on their use of these allocations in annual research and development reports. These reports identify total, aggregated expenditure on national priority areas, including cancer. They do not provide details of research into particular cancer sites. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. At the same time, an increasing amount of NHS research funding was awarded competitively through new NIHR programmes and schemes.</p><p> </p><p> </p><p> </p><p>Expenditure by the NIHR through research programmes, research centres and units, and research training awards on mesothelioma research is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>2006-07</p><p>£ million</p></td><td><p>2007-08</p><p>£ million</p></td><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£ million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£ million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Total spend by the NIHR on mesothelioma research is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>The NIHR invests in infrastructure for experimental medicine to translate scientific developments into benefits for patients. This infrastructure includes biomedical centres and units, clinical research facilities, and experimental cancer medicine centres. The NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London has contributed to the funding of recent research on the use of TRAIL (tumour necrosis factor-related apoptosis-inducing ligand)-expressing mesenchymal stem cells to reduce tumour growth in malignant mesothelioma.</p><p> </p><p> </p><p> </p><p>The following table provides expenditure by the Medical Research Council on research related to mesothelioma over the past six years. Information on spend from 2004-05 to 2007-08 was not available within the timescale.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£ million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£ million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.7</p></td><td><p>2.4</p></td><td><p>2.2</p></td><td><p>1.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>In April 2014, I convened a high level meeting between the Association of British Insurers and the British Lung Foundation (BLF) to discuss how insurers can remain engaged in support for mesothelioma research. Two insurers – Aviva and Zurich – who participated in the earlier donation by insurers of £3 million to the BLF, have agreed to each donate £250,000 per annum to the BLF for mesothelioma research over the next two years – a combined total of £1 million.</p><p> </p>
star this property answering member printed Earl Howe more like this
star this property grouped question UIN HL5851 more like this
star this property question first answered
less than 2015-03-25T16:19:48.59Zmore like thismore than 2015-03-25T16:19:48.59Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
unstar this property tabling member
547
unstar this property label Biography information for Lord Wigley more like this